How do Carbonic Anhydrase Inhibitors help manage glaucoma?

Carbonic Anhydrase Inhibitors play a significant role in managing glaucoma primarily by decreasing the production of intraocular fluid. These medications work by inhibiting the enzyme carbonic anhydrase, which is involved in the secretion of bicarbonate ions. When the action of this enzyme is inhibited, there's a reduction in the production of aqueous humor, the fluid that fills the front part of the eye.

With less aqueous humor produced, the intraocular pressure is subsequently lowered, which is beneficial for patients with glaucoma, a condition characterized by elevated intraocular pressure that can lead to optic nerve damage and vision loss.

The other answers reflect incorrect mechanisms of action or objectives of treatment in glaucoma management. For instance, increasing intraocular pressure contradicts the therapeutic goal, while improving drainage of intraocular fluid pertains more to other types of glaucoma medications, such as prostaglandin analogs. Enhancing visual acuity is not a direct effect of Carbonic Anhydrase Inhibitors; rather, the objective is to control intraocular pressure to prevent further damage to vision.